News and Trends 9 Jan 2023
STALICLA signs agreement with Novartis on neurodevelopmental disorders
STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as…